DOI QR코드

DOI QR Code

Intrapleural or Intraperitoneal Lobaplatin for Treatment of Patients with Malignant Pleural Effusion or Ascites

  • Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Wei, Guo-Li (Department of Medical Oncology, Jiangsu Province Hospital on Integration of Chinese and Western Medicine) ;
  • Huo, Jie-Ge (Department of Medical Oncology, Jiangsu Province Hospital on Integration of Chinese and Western Medicine) ;
  • Wang, Xiao-Ning (Department of Medical Oncology, Jiangsu Province Hospital on Integration of Chinese and Western Medicine) ;
  • Lu, Yan-Yan (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Wu, Xue-Yan (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Liu, Jin (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Xiang, Jin (Department of Research, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Feng, Ji-Feng (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
  • Published : 2013.04.30

Abstract

Aims: To explore efficacy and side effects of intrapleural or intraperitoneal lobaplatin for treating patients with malignant pleural or peritoneal effusions. Methods: Patients in Jiangsu Cancer Hospital and Research Institute with cytologically confirmed solid tumors complicated with malignant pleural effusion or ascites were enrolled into this study. Lobaplatin (20-30 $mg/m^2$) was intrapleurally or intraperitoneally infused for patients with malignant pleural effusion or ascites. Results: From 2012 to 2013, intrapleural or intraperitonea lobaplatin was administered for patients with colorectal or uterus cancer who were previous treated for malignant pleural effusion or ascites. Partial response was achieved for them. Main side effects were nausea/vomiting, and bone marrow suppression. No treatment related deaths occurred. Conclusion: Intrapleural or intraperitoneal infusion of lobaplatin is a safe treatment for patients with malignant pleural effusion or ascites, and the treatment efficacy is encouraging.

References

  1. Eliopoulos AG, Kerr DJ, Maurer HR, Hilgard P, Spandidos DA (1995). Induction of the c-myc but not the cH-ras promoter by platinum compounds. Biochem Pharmacol, 50, 33-8. https://doi.org/10.1016/0006-2952(95)00085-E
  2. Awasthi A, Gupta N, Srinivasan R, et al (2007). Cytopathological spectrum of unusual malignant pleural effusions at a tertiary care centre in north India. Cytopathology, 18, 28-32.
  3. Ayantunde AA, Parsons SL (2007). Pattern and prognostic factors inpatients with malignant ascites, a retrospective study. Ann Oncol, 18, 945-9. https://doi.org/10.1093/annonc/mdl499
  4. Bielsa S, Martin-Juan J, Porcel JM, et al (2008). Diagnostic and prognostic implications of pleural adhesions in malignant effusions. J Thorac Oncol, 3, 1251-6. https://doi.org/10.1097/JTO.0b013e318189f53d
  5. Bogholo GV, Lerza R, Bottino GB, et al(1991). Regional pharmaco-kinetics selectivity of intrapleural cisplatin. Eur J Cancer, 27, 839-42. https://doi.org/10.1016/0277-5379(91)90129-2
  6. Esposito M, Lerza R, Vannozzi M, et al (1994). Pharmacokjnetic evaluation of intrapleural carboplatin in patients with malignant pleural effusion. Drug Invest, 8, 352-60. https://doi.org/10.1007/BF03257450
  7. Gao LL, Huang XE, Zhang Q, et al (2011). 14.A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China, final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
  8. Gietema JA , Veldhuis GJ , Guchelaar HJ, et al (1995). Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Br J Cancer, 71, 1302-7. https://doi.org/10.1038/bjc.1995.252
  9. Gietema JA, de Vries EG, Sleijfer DT, et al (1993). A phase I study of 1, 2-diamminomethy l-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. Br J Cancer, 67, 396-401. https://doi.org/10.1038/bjc.1993.73
  10. Gietema JA, Guchelaar HJ, de Vries EG, et al (1993). A phase I study of lobaplatin (D-19466) administered by 72 h continuous infusion. Anticancer Drugs, 4, 51-5. https://doi.org/10.1097/00001813-199302000-00007
  11. Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pac J Cancer Prev, 13, 1873-5. https://doi.org/10.7314/APJCP.2012.13.5.1873
  12. Hartman DL, Gaither JM, Kesler KA et al (1993). Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg, 105, 743-7.
  13. Hausheer FH, Yarbro JW (1985). Diagnosis and treatment of malignant pleural effusion. Semin Oncol, 12, 54-75.
  14. Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev, 12, 2797-800.
  15. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 11, 1059-62.
  16. Johnston WW (1985). The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer, 56, 905-9. https://doi.org/10.1002/1097-0142(19850815)56:4<905::AID-CNCR2820560435>3.0.CO;2-U
  17. Kitani K, Morimoto T, Shibata N, et al (2001). Effects of intraperitoneal injection of low-dose CDDP on 3 patients with ascites owing to peritonitis carcinomatosa of gastric and colorectal carcinoma. Gan To Kagaku Ryoho, 28, 1666-8.
  18. Kitayama J, Ishigami H, Kaisaki S, et al (2010). Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer. Oncology, 78, 40-6.
  19. Lee YC, Yasay JR, Johnson JE, et al (2002).Comparing transforming growth factor-beta2, talc and bleomycin as pleurodesing agents in sheep. Respirology, 7, 209-16. https://doi.org/10.1046/j.1440-1843.2002.00397.x
  20. Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin(R) administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
  21. Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4. https://doi.org/10.7314/APJCP.2012.13.1.301
  22. Li CG, Huang XE, Li Y, et al (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90.
  23. Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9.
  24. Link KH, Roitman M, Holtappels M, et al (2003). Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. Surg Oncol Clin N Am, 12, 865-72. https://doi.org/10.1016/S1055-3207(03)00050-4
  25. Liu W, Li SY, Huang XE, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from rosa roxburghii tratt and fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14. https://doi.org/10.7314/APJCP.2012.13.5.2409
  26. Manegold, Drings C, Gatzemeier PU, et al (1996). Lobaplatin (D-19466) in Patients with advanced non-small-cell lung cancer, a trial of the association for medical oncology (AIO) phase II study group. Onkologie, 19, 248-251. https://doi.org/10.1159/000218806
  27. Degardin M, Armand JP, Chevallier B, et al (1995). A Clinical Screening Cooperative Group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer. New Drugs, 13, 253-5. https://doi.org/10.1007/BF00873809
  28. McKeage MJ (2001). Lobaplatin, a new antitumour platinum drug. Exp Opin Invest Drugs, 10, 119-28. https://doi.org/10.1517/13543784.10.1.119
  29. Mross K, Meyberg F, Fieberg HH, et al (1992). Pharmacokinetic and pharmacodynamic study with lobaplatin (D-19466), a new platinum complex, after bolus administration. Onkologie, 15, 139-46. https://doi.org/10.1159/000217347
  30. Naitoh H, Kawaguch A, Yamamoto H, et al (2004). Measurement of docetaxel concentration in blood and ascites after drip infusion into each vessel and intraperitoneal cavity of gastric cancer. Gan To Kagaku Ryoho, 31, 2031-4.
  31. Ostrowski MJ (1986). An assessment of the long-term results of controlling the reaccumulation of malignant effusions using intracavity bleomycin. Cancer, 57, 721-7. https://doi.org/10.1002/1097-0142(19860215)57:4<721::AID-CNCR2820570407>3.0.CO;2-5
  32. Putnam JB Jr, Light RW, Rodriguez RM, et al (1999). A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the manage-ment of malignant pleural effusions. Cancer, 86, 1992-9. https://doi.org/10.1002/(SICI)1097-0142(19991115)86:10<1992::AID-CNCR16>3.0.CO;2-M
  33. Sahn SA (1997). Pleural diseases related to metastatic malignancies. Eur Respir J, 10, 1907-13. https://doi.org/10.1183/09031936.97.10081907
  34. Saka H, Shimokata K, Watanabe A, et al (1994). Randomized comparision of OK-432 and bleomycin in intrapleural therapy for malignant pleural effusion. Proc Am Soc Clin Oncol, 13, 450.
  35. Schilsky RL, Choi KE, Grayhack J, et al (1990). Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J Clin Oncol, 8, 2054-61.
  36. Seto T, Ushijima S, Yamamoto H, et al (2006). Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer, a multiinstitutional phase II trial. Br J Cancer, 95, 717-21 https://doi.org/10.1038/sj.bjc.6603319
  37. Shu J, Li CG, Liu YC, et al (2012). Comparison of Serum Tumor Associated Material (TAM) with Conventional Biomarkers in Cancer Patients. Asian Pac J Cancer Prev, 13, 2399-403. https://doi.org/10.7314/APJCP.2012.13.5.2399
  38. Sternberg CN, de Mulder P, Fossa S, et al (1997). Lobaplatin in advanced urothelial tract tumors. Ann Oncol, 8, 695-6. https://doi.org/10.1023/A:1008269432176
  39. Voegeli R, Schumacher W, Engel J, et al (1990). D-19466, a new cyclobutane-platinum complex with antitumour activity. J Cancer Res Clin, 116, 439-42. https://doi.org/10.1007/BF01612990
  40. Welink J, Boven E, Ver morken JB, et al (1999). Pharmacokinetics and pharmacodynamics of lobaplatin(D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function. Clin Cancer Res, 5, 2349-58.
  41. Wheate NJ, Walker S, Craig GE, et al (2010). The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans, 39, 8113-27. https://doi.org/10.1039/c0dt00292e
  42. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
  43. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar(R) combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
  44. Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.
  45. Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in Asians but not Caucasians. Asian Pac J Cancer Prev, 13, 2349-54. https://doi.org/10.7314/APJCP.2012.13.5.2349
  46. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
  47. Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
  48. Yu DS, Huang XE, Zhou JN, et al (2012). Comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, 13, 2339-40. https://doi.org/10.7314/APJCP.2012.13.5.2339
  49. Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility, a metaanalysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
  50. Zhang XZ, Huang XE, Xu YL, et al (2012). Phase II study on voriconazole for treatment of Chinese patients with malignant hematological disorders and invasive aspergillosis. Asian Pac J Cancer Prev, 13, 2415-8. https://doi.org/10.7314/APJCP.2012.13.5.2415
  51. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/ Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer, a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.

Cited by

  1. Role of MYH Polymorphisms in Sporadic Colorectal Cancer in China: A Case-control, Population-based Study vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6403
  2. Colorectal Cancer Screening in High-risk Populations: a Survey of Cognition among Medical Professionals in Jiangsu, China vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6487
  3. Pemetrexed as a Component of First-, Second- and Third-line Chemotherapy in Treating Patients with Metastatic Lung Adenocarcinoma vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6663
  4. Helicobacter pylori Infection and the Risk of Colorectal Adenoma and Adenocarcinoma: an Updated Meta-analysis of Different Testing Methods vol.14, pp.12, 2013, https://doi.org/10.7314/APJCP.2013.14.12.7613
  5. Phase II Study on Pemetrexed-based Chemotherapy in Treating Patients with Metastatic Gastric Cancer not Responding to Prior Palliative Chemotherapy vol.14, pp.5, 2013, https://doi.org/10.7314/APJCP.2013.14.5.2703
  6. Phase II Study on Breast Conservative Surgery Plus Chemo- and Radiotherapy in Treating Chinese Patients with Early Staged Breast Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3747
  7. Potential Therapeutic Efficacy of Curcumin in Liver Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3855
  8. Hsa-miR-181a-5p Expression and Effects on Cell Proliferation in Gastric Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3871
  9. Risk Assessment on Anastomotic Leakage after Rectal Cancer Surgery: An Analysis of 753 Patients vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4447
  10. ) Combined with Chemotherapy in Treating Patients with Advanced Lung Adenocarcinoma vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4791
  11. Clinical Study on Mannan Peptide Combined with TP Regimen in Treating Patients with Non-small Cell Lung Cancer vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4801
  12. Acidic Pelvic Drainage as a Predictive Factor For Anastomotic Leakage after Surgery for Patients with Rectal Cancer vol.14, pp.9, 2013, https://doi.org/10.7314/APJCP.2013.14.9.5441
  13. Characterization and differentiation of body fluids, putrefaction fluid, and blood using Hounsfield unit in postmortem CT vol.128, pp.5, 2014, https://doi.org/10.1007/s00414-014-1030-0
  14. Clinical Study on Safety of Cantharidin Sodium and Shenmai Injection Combined with Chemotherapy in Treating Patients with Breast Cancer Postoperatively vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5597
  15. A Predictive Model for Evaluating Responsiveness to Pemetrexed Treatment in Patients with Advanced Colorectal Cancer vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5941
  16. Application of Lobaplatin in Trans-catheter Arterial Chemoembolization for Primary Hepatic Carcinoma vol.15, pp.2, 2014, https://doi.org/10.7314/APJCP.2014.15.2.647
  17. Lobaplatin Combined Floxuridine/Pirarubicin-based Transcatheter Hepatic Arterial Chemoembolization for Unresectable Primary Hepatocellular Carcinoma vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2057
  18. v6 and E-cadherin and Lymphatic Metastasis in Non-small Cell Lung Cancer vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2221
  19. Anti-Proliferation Effects and Molecular Mechanisms of Action of Tetramethypyrazine on Human SGC-7901 Gastric Carcinoma Cells vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3581
  20. Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3951
  21. Gimeracil/oteracil/tegafur/oxaliplatin vol.1517, pp.1, 2014, https://doi.org/10.1007/s40278-014-3163-9
  22. Postmortem quantitative 1.5-T MRI for the differentiation and characterization of serous fluids, blood, CSF, and putrefied CSF vol.129, pp.5, 2015, https://doi.org/10.1007/s00414-015-1218-y
  23. Clinical Study on Safety and Efficacy of JiSaiXin (Recombinant Human Granulocyte Colony Stimulating Factor Injection Manufactured in China) for Chinese Undergoing Chemotherapy vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.299
  24. A Randomized Controlled Trial Comparing Clinical Outcomes and Toxicity of Lobaplatin- Versus Cisplatin-Based Concurrent Chemotherapy Plus Radiotherapy and High-Dose-Rate Brachytherapy for FIGO Stage II and III Cervical Cancer vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5957
  25. Screening for Patients with Non-small Cell Lung Cancer Who Could Survive Long Term Chemotherapy vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.647
  26. Analysis on Early Detection of Lung Cancer by PET/CT Scan vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2215
  27. Radioactive Seed Implantation and Lobaplatin Chemotherapy Are Safe and Effective in Treating Patients with Advanced Lung Cancer vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.4003
  28. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies vol.14, pp.1, 2016, https://doi.org/10.1186/s12957-016-1004-4
  29. A targeted drug delivery system based on carbon nanotubes loaded with lobaplatin toward liver cancer cells vol.33, pp.17, 2018, https://doi.org/10.1557/jmr.2018.197
  30. Intrapleural combination therapy with lobaplatin and erythromycin for non-small cell lung cancer-mediated malignant pleural effusion vol.9, pp.8, 2018, https://doi.org/10.1111/1759-7714.12768